Key result
Enfortumab vedotin stabilizes right ventricular metastasis from sarcomatoid urethral carcinoma despite eventual pelvic progression.
Why the study?
Primary urethral carcinoma is an uncommon malignancy, and cardiac metastasis is a rare event (~4% of cases) that poses significant diagnostic challenges, particularly in distinguishing myocardial tumors from intracavitary thrombi.
Case Report (n=1)
No
This case report demonstrates the critical utility of sequential multimodality cardiac imaging (echocardiography, FDG PET-CT, cardiac CT, and CMR) in distinguishing a rare right ventricular metastasis from an intracavitary thrombus in a patient with sarcomatoid urethral carcinoma when endomyocardial biopsy is contraindicated.
May support cardiac metastasis control with enfortumab vedotin in urothelial carcinoma; hypothesis-generating for interlesional heterogeneity and needs prospective validation.
Primary urethral carcinoma is an uncommon malignancy, and cardiac metastasis represents a rare event (~4% of cases) that poses significant diagnostic challenges, particularly in distinguishing myocardial tumors from intracavitary thrombi. Here we report a 54-year-old male diagnosed with cT4N0M0 sarcomatoid urothelial carcinoma of the bulbar urethra. Following neoadjuvant dose-dense MVAC and radical surgery (ypT2N0, PD-L1 TPS 20%), adjuvant nivolumab was initiated. Six months after surgery, he developed locoregional recurrence and an expanding right ventricular mass. Multimodality cardiac imaging—including contrast echocardiography, FDG PET-CT, cardiac CT, and cardiac MRI—demonstrated a solid myocardial lesion with intracavitary extension and adjacent myocardial infiltration, considered highly suspicious for cardiac metastasis in the context of concurrent extracardiac progression. Histological confirmation was not obtained because of the procedural risk associated with extensive right ventricular involvement. Treatment with enfortumab vedotin yielded relative stability of the cardiac and pulmonary metastases; however, relentless locoregional progression occurred, illustrating interlesional response heterogeneity. The patient subsequently received palliative radiotherapy, and best supportive care before passing away 17 months after initial diagnosis. This case underscores the vital role of multimodal imaging in the differential diagnosis of cardiac masses in oncological patients with concurrent thromboembolic risk and its interpretation in conjunction with the disease course when pathology confirmation cannot be obtained. Furthermore, it highlights the therapeutic complexity and dismal prognosis associated with sarcomatoid histology in advanced urethral carcinoma.
No takes yet. Share an insight, caveat, or question.
Yaringaño et al. (2026) conducted a case report in Sarcomatoid urothelial carcinoma of the bulbar urethra with right ventricular metastasis (n=1). Enfortumab vedotin was evaluated on Overall survival and disease response. Enfortumab vedotin stabilized a 58x53x38 mm right ventricular metastasis in a 54-year-old man with sarcomatoid urethral carcinoma, though pelvic progression led to death at 17 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: